1
|
Clerin V, Saito H, Filipski KJ, Nguyen AH, Garren J, Kisucka J, Reyes M, Jüppner H. Selective pharmacological inhibition of the sodium-dependent phosphate cotransporter NPT2a promotes phosphate excretion. J Clin Invest 2020; 130:6510-6522. [PMID: 32853180 PMCID: PMC7685737 DOI: 10.1172/jci135665] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2019] [Accepted: 08/20/2020] [Indexed: 12/16/2022] Open
Abstract
The sodium-phosphate cotransporter NPT2a plays a key role in the reabsorption of filtered phosphate in proximal renal tubules, thereby critically contributing to phosphate homeostasis. Inadequate urinary phosphate excretion can lead to severe hyperphosphatemia as in tumoral calcinosis and chronic kidney disease (CKD). Pharmacological inhibition of NPT2a may therefore represent an attractive approach for treating hyperphosphatemic conditions. The NPT2a-selective small-molecule inhibitor PF-06869206 was previously shown to reduce phosphate uptake in human proximal tubular cells in vitro. Here, we investigated the acute and chronic effects of the inhibitor in rodents and report that administration of PF-06869206 was well tolerated and elicited a dose-dependent increase in fractional phosphate excretion. This phosphaturic effect lowered plasma phosphate levels in WT mice and in rats with CKD due to subtotal nephrectomy. PF-06869206 had no effect on Npt2a-null mice, but promoted phosphate excretion and reduced phosphate levels in normophophatemic mice lacking Npt2c and in hyperphosphatemic mice lacking Fgf23 or Galnt3. In CKD rats, once-daily administration of PF-06869206 for 8 weeks induced an unabated acute phosphaturic and hypophosphatemic effect, but had no statistically significant effect on FGF23 or PTH levels. Selective pharmacological inhibition of NPT2a thus holds promise as a therapeutic option for genetic and acquired hyperphosphatemic disorders.
Collapse
Affiliation(s)
- Valerie Clerin
- Pfizer Inc., Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA
| | | | - Kevin J. Filipski
- Pfizer Inc., Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA
| | - An Hai Nguyen
- Pfizer Inc., Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA
| | - Jeonifer Garren
- Pfizer Inc., Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA
| | - Janka Kisucka
- Pfizer Inc., Worldwide Research, Development and Medical, Cambridge, Massachusetts, USA
| | | | - Harald Jüppner
- Endocrine Unit and
- Pediatric Nephrology Unit, Massachusetts General Hospital (MGH) and Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
2
|
Zhong X, Jagarlapudi S, Weng Y, Ly M, Rouse JC, McClure K, Ishino T, Zhang Y, Sousa E, Cohen J, Tzvetkova B, Cote K, Scarcelli JJ, Johnson K, Palandra J, Apgar JR, Yaddanapudi S, Gonzalez-Villalobos RA, Opsahl AC, Lam K, Yao Q, Duan W, Sievers A, Zhou J, Ferguson D, D'Antona A, Zollner R, Zhu HL, Kriz R, Lin L, Clerin V. Structure-function relationships of the soluble form of the antiaging protein Klotho have therapeutic implications for managing kidney disease. J Biol Chem 2020; 295:3115-3133. [PMID: 32005658 DOI: 10.1074/jbc.ra119.012144] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 01/20/2020] [Indexed: 01/28/2023] Open
Abstract
The fortuitously discovered antiaging membrane protein αKlotho (Klotho) is highly expressed in the kidney, and deletion of the Klotho gene in mice causes a phenotype strikingly similar to that of chronic kidney disease (CKD). Klotho functions as a co-receptor for fibroblast growth factor 23 (FGF23) signaling, whereas its shed extracellular domain, soluble Klotho (sKlotho), carrying glycosidase activity, is a humoral factor that regulates renal health. Low sKlotho in CKD is associated with disease progression, and sKlotho supplementation has emerged as a potential therapeutic strategy for managing CKD. Here, we explored the structure-function relationship and post-translational modifications of sKlotho variants to guide the future design of sKlotho-based therapeutics. Chinese hamster ovary (CHO)- and human embryonic kidney (HEK)-derived WT sKlotho proteins had varied activities in FGF23 co-receptor and β-glucuronidase assays in vitro and distinct properties in vivo Sialidase treatment of heavily sialylated CHO-sKlotho increased its co-receptor activity 3-fold, yet it remained less active than hyposialylated HEK-sKlotho. MS and glycopeptide-mapping analyses revealed that HEK-sKlotho is uniquely modified with an unusual N-glycan structure consisting of N,N'-di-N-acetyllactose diamine at multiple N-linked sites, one of which at Asn-126 was adjacent to a putative GalNAc transfer motif. Site-directed mutagenesis and structural modeling analyses directly implicated N-glycans in Klotho's protein folding and function. Moreover, the introduction of two catalytic glutamate residues conserved across glycosidases into sKlotho enhanced its glucuronidase activity but decreased its FGF23 co-receptor activity, suggesting that these two functions might be structurally divergent. These findings open up opportunities for rational engineering of pharmacologically enhanced sKlotho therapeutics for managing kidney disease.
Collapse
Affiliation(s)
- Xiaotian Zhong
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139.
| | - Srinath Jagarlapudi
- Internal Medicine, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Yan Weng
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Mellisa Ly
- Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts 01810
| | - Jason C Rouse
- Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts 01810
| | - Kim McClure
- Internal Medicine, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Tetsuya Ishino
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Yan Zhang
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Eric Sousa
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Justin Cohen
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Boriana Tzvetkova
- Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts 01810
| | - Kaffa Cote
- Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts 01810
| | - John J Scarcelli
- Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts 01810
| | - Keith Johnson
- Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts 01810
| | - Joe Palandra
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - James R Apgar
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Suma Yaddanapudi
- Internal Medicine, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | | | - Alan C Opsahl
- Internal Medicine, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Khetemenee Lam
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Qing Yao
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Weili Duan
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Annette Sievers
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Jing Zhou
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Darren Ferguson
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Aaron D'Antona
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Richard Zollner
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Hongli L Zhu
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Ron Kriz
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Laura Lin
- BioMedicine Design, Pfizer Worldwide Research, Cambridge, Massachusetts 02139
| | - Valerie Clerin
- Internal Medicine, Pfizer Worldwide Research, Cambridge, Massachusetts 02139.
| |
Collapse
|
3
|
Filipski KJ, Sammons MF, Bhattacharya SK, Panteleev J, Brown JA, Loria PM, Boehm M, Smith AC, Shavnya A, Conn EL, Song K, Weng Y, Facemire C, Jüppner H, Clerin V. Discovery of Orally Bioavailable Selective Inhibitors of the Sodium-Phosphate Cotransporter NaPi2a (SLC34A1). ACS Med Chem Lett 2018; 9:440-445. [PMID: 29795756 DOI: 10.1021/acsmedchemlett.8b00013] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Accepted: 04/04/2018] [Indexed: 11/30/2022] Open
Abstract
Sodium-phosphate cotransporter 2a, or NaPi2a (SLC34A1), is a solute-carrier (SLC) transporter located in the kidney proximal tubule that reabsorbs glomerular-filtered phosphate. Inhibition of NaPi2a may enhance urinary phosphate excretion and correct maladaptive mineral and hormonal derangements associated with increased cardiovascular risk in chronic kidney disease-mineral and bone disorder (CKD-MBD). To date, only nonselective NaPi inhibitors have been described. Herein, we detail the discovery of the first series of selective NaPi2a inhibitors, resulting from optimization of a high-throughput screening hit. The oral PK profile of inhibitor PF-06869206 (6f) in rodents allows for the exploration of the pharmacology of selective NaPi2a inhibition.
Collapse
Affiliation(s)
- Kevin J. Filipski
- Pfizer Worldwide Research & Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Matthew F. Sammons
- Pfizer Worldwide Research & Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Samit K. Bhattacharya
- Pfizer Worldwide Research & Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Jane Panteleev
- Pfizer Worldwide Research & Development, 558 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Janice A. Brown
- Pfizer Worldwide Research & Development, 558 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Paula M. Loria
- Pfizer Worldwide Research & Development, 558 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Markus Boehm
- Pfizer Worldwide Research & Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Aaron C. Smith
- Pfizer Worldwide Research & Development, 558 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Andre Shavnya
- Pfizer Worldwide Research & Development, 558 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Edward L. Conn
- Pfizer Worldwide Research & Development, 558 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Kun Song
- Pfizer Worldwide Research & Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Yan Weng
- Pfizer Worldwide Research & Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Carie Facemire
- Pfizer Worldwide Research & Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States
| | - Harald Jüppner
- Endocrine Unit and Pediatric Nephrology Unit, Thier 10, Massachusetts General Hospital and Harvard Medical School, 50 Blossom Street, Boston, Massachusetts 02114, United States
| | - Valerie Clerin
- Pfizer Worldwide Research & Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
4
|
Menhaji-Klotz E, Hesp KD, Londregan AT, Kalgutkar AS, Piotrowski DW, Boehm M, Song K, Ryder T, Beaumont K, Jones RM, Atkinson K, Brown JA, Litchfield J, Xiao J, Canterbury DP, Burford K, Thuma BA, Limberakis C, Jiao W, Bagley SW, Agarwal S, Crowell D, Pazdziorko S, Ward J, Price DA, Clerin V. Discovery of a Novel Small-Molecule Modulator of C–X–C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis. J Med Chem 2018; 61:3685-3696. [DOI: 10.1021/acs.jmedchem.8b00190] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
- Elnaz Menhaji-Klotz
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Kevin D. Hesp
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Allyn T. Londregan
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Amit S. Kalgutkar
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - David W. Piotrowski
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Markus Boehm
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Kun Song
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Tim Ryder
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Kevin Beaumont
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Rhys M. Jones
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Karen Atkinson
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Janice A. Brown
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - John Litchfield
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Jun Xiao
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Daniel P. Canterbury
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Kristen Burford
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Benjamin A. Thuma
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Chris Limberakis
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Wenhua Jiao
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Scott W. Bagley
- Pfizer Worldwide Research & Development, Groton, Connecticut 06340, United States
| | - Saket Agarwal
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Danielle Crowell
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Stephen Pazdziorko
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Jessica Ward
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - David A. Price
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| | - Valerie Clerin
- Pfizer Worldwide Research & Development, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
5
|
Scheele W, Diamond S, Gale J, Clerin V, Tamimi N, Le V, Walley R, Grover-Páez F, Perros-Huguet C, Rolph T, El Nahas M. Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy. J Am Soc Nephrol 2016; 27:3459-3468. [PMID: 27113485 DOI: 10.1681/asn.2015050473] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2015] [Accepted: 02/23/2016] [Indexed: 12/31/2022] Open
Abstract
Diabetic nephropathy (DN) is the leading cause of ESRD worldwide. Reduced bioavailability or uncoupling of nitric oxide in the kidney, leading to decreased intracellular levels of the nitric oxide pathway effector molecule cyclic guanosine monophosphate (cGMP), has been implicated in the progression of DN. Preclinical studies suggest that elevating the cGMP intracellular pool through inhibition of the cGMP-hydrolyzing enzyme phosphodiesterase type 5 (PDE5) might exert renoprotective effects in DN. To test this hypothesis, the novel, highly specific, and long-acting PDE5 inhibitor, PF-00489791, was assessed in a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group trial of subjects with type 2 diabetes mellitus and overt nephropathy receiving angiotensin converting enzyme inhibitor or angiotensin receptor blocker background therapy. In total, 256 subjects with an eGFR between 25 and 60 ml/min per 1.73 m2 and macroalbuminuria defined by a urinary albumin-to-creatinine ratio >300 mg/g, were randomly assigned 3:1, respectively, to receive PF-00489791 (20 mg) or placebo orally, once daily for 12 weeks. Using the predefined primary assessment of efficacy (Bayesian analysis with informative prior), we observed a significant reduction in urinary albumin-to-creatinine ratio of 15.7% (ratio 0.843; 95% credible interval 0.73 to 0.98) in response to the 12-week treatment with PF-00489791 compared with placebo. PF-00489791 was safe and generally well tolerated in this patient population. Most common adverse events were mild in severity and included headache and upper gastrointestinal events. In conclusion, the safety and efficacy profile of PDE5 inhibitor PF-00489791 supports further investigation as a novel therapy to improve renal outcomes in DN.
Collapse
Affiliation(s)
| | - Susan Diamond
- San Antonio Kidney Disease Center, San Antonio, Texas
| | | | | | | | - Vu Le
- Pfizer Inc., Cambridge, Massachusetts
| | | | - Fernando Grover-Páez
- Institute of Experimental and Clinical Therapeutics, Universidad de Guadalajara, Guadalajara, México; and
| | | | | | | |
Collapse
|
6
|
Huang A, Moretto A, Janz K, Lowe M, Bedard PW, Tam S, Di L, Clerin V, Sushkova N, Tchernychev B, Tsao DHH, Keith JC, Shaw GD, Schaub RG, Wang Q, Kaila N. Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury. J Med Chem 2010; 53:6003-17. [PMID: 20718494 DOI: 10.1021/jm9013696] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the alpha position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.
Collapse
Affiliation(s)
- Adrian Huang
- Pfizer Global Research and Development, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Quinet EM, Basso MD, Halpern AR, Yates DW, Steffan RJ, Clerin V, Resmini C, Keith JC, Berrodin TJ, Feingold I, Zhong W, Hartman HB, Evans MJ, Gardell SJ, DiBlasio-Smith E, Mounts WM, LaVallie ER, Wrobel J, Nambi P, Vlasuk GP. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. J Lipid Res 2009; 50:2358-70. [PMID: 19318684 DOI: 10.1194/jlr.m900037-jlr200] [Citation(s) in RCA: 78] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Liver X receptors (LXRs) are ligand-activated transcription factors that coordinate regulation of gene expression involved in several cellular functions but most notably cholesterol homeostasis encompassing cholesterol transport, catabolism, and absorption. WAY-252623 (LXR-623) is a highly selective and orally bioavailable synthetic modulator of LXR, which demonstrated efficacy for reducing lesion progression in the murine LDLR(-/-) atherosclerosis model with no associated increase in hepatic lipogenesis either in this model or Syrian hamsters. In nonhuman primates with normal lipid levels, WAY-252623 significantly reduced total (50-55%) and LDL-cholesterol (LDLc) (70-77%) in a time- and dose-dependent manner as well as increased expression of the target genes ABCA1/G1 in peripheral blood cells. Statistically significant decreases in LDLc were noted as early as day 7, reached a maximum by day 28, and exceeded reductions observed for simvastatin alone (20 mg/kg). Transient increases in circulating triglycerides and liver enzymes reverted to baseline levels over the course of the study. Complementary microarray analysis of duodenum and liver gene expression revealed differential activation of LXR target genes and suggested no direct activation of hepatic lipogenesis. WAY-252623 displays a unique and favorable pharmacological profile suggesting synthetic LXR ligands with these characteristics may be suitable for evaluation in patients with atherosclerotic dyslipidemia.
Collapse
Affiliation(s)
- Elaine M Quinet
- Department of Cardiovascular/Metabolic Diseases and Nuclear Receptor Biology, Wyeth Research, Collegeville, PA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Clerin V, Shih HH, Deng N, Hebert G, Resmini C, Shields KM, Feldman JL, Winkler A, Albert L, Maganti V, Wong A, Paulsen JE, Keith JC, Vlasuk GP, Pittman DD. Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis. Atherosclerosis 2008; 201:53-66. [DOI: 10.1016/j.atherosclerosis.2008.01.016] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2007] [Revised: 01/09/2008] [Accepted: 01/28/2008] [Indexed: 10/22/2022]
|
9
|
Wrobel J, Steffan R, Bowen SM, Magolda R, Matelan E, Unwalla R, Basso M, Clerin V, Gardell SJ, Nambi P, Quinet E, Reminick JI, Vlasuk GP, Wang S, Feingold I, Huselton C, Bonn T, Farnegardh M, Hansson T, Nilsson AG, Wilhelmsson A, Zamaratski E, Evans MJ. Indazole-Based Liver X Receptor (LXR) Modulators with Maintained Atherosclerotic Lesion Reduction Activity but Diminished Stimulation of Hepatic Triglyceride Synthesis. J Med Chem 2008; 51:7161-8. [DOI: 10.1021/jm800799q] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Jay Wrobel
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Robert Steffan
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - S. Marc Bowen
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Ronald Magolda
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Edward Matelan
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Rayomand Unwalla
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Michael Basso
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Valerie Clerin
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Stephen J. Gardell
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Ponnal Nambi
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Elaine Quinet
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Jason I. Reminick
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - George P. Vlasuk
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Shuguang Wang
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Irene Feingold
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Christine Huselton
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Tomas Bonn
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Mathias Farnegardh
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Tomas Hansson
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Annika Goos Nilsson
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Anna Wilhelmsson
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Edouard Zamaratski
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| | - Mark J. Evans
- Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, Pennsylvania 19426, and Karo Bio AB, Huddinge, Sweden
| |
Collapse
|
10
|
Bedard PW, Clerin V, Sushkova N, Tchernychev B, Antrilli T, Resmini C, Keith JC, Hennan JK, Kaila N, Debernardo S, Janz K, Wang Q, Crandall DL, Schaub RG, Shaw GD, Carter LL. Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther 2007; 324:497-506. [PMID: 18024786 DOI: 10.1124/jpet.107.128124] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
P-selectin plays a significant and well documented role in vascular disease by mediating leukocyte and platelet rolling and adhesion. This study characterizes the in vitro activity, pharmacokinetic properties, and the anti-inflammatory and antithrombotic efficacy of the orally active P-selectin small-molecule antagonist PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid; molecular mass, 367.83]. Biacore and cell-based assays were used to demonstrate the ability of PSI-697 to dose dependently inhibit the binding of human P-selectin to human P-selectin glycoprotein ligand-1, inhibiting 50% of binding at 50 to 125 microM. The pharmacokinetics of PSI-697 in rats were characterized by low clearance, short half-life, low volume of distribution, and moderate apparent oral bioavailability. A surgical inflammation model, using exteriorized rat cremaster venules, demonstrated that PSI-697 (50 mg/kg p.o.) significantly reduced the number of rolling leukocytes by 39% (P < 0.05) versus vehicle control. In a rat venous thrombosis model, PSI-697 (100 mg/kg p.o.) reduced thrombus weight by 18% (P < 0.05) relative to vehicle, without prolonging bleeding time. Finally, in a rat carotid injury model, PSI-697 (30 or 15 mg/kg p.o.) administered 1 h before arterial injury and once daily thereafter for 13 days resulted in dose-dependent decreases in intima/media ratios of 40.2% (P = 0.025) and 25.7% (P = 0.002) compared with vehicle controls. These data demonstrate the activity of PSI-697 in vitro and after oral administration in animal models of both arterial and venous injury and support the clinical evaluation of this novel antagonist of P-selectin in atherothrombotic and venous thrombotic indications.
Collapse
|
11
|
Hu B, Jetter J, Kaufman D, Singhaus R, Bernotas R, Unwalla R, Quinet E, Savio D, Halpern A, Basso M, Keith J, Clerin V, Chen L, Liu QY, Feingold I, Huselton C, Azam F, Goos-Nilsson A, Wilhelmsson A, Nambi P, Wrobel J. Further modification on phenyl acetic acid based quinolines as liver X receptor modulators. Bioorg Med Chem 2007; 15:3321-33. [PMID: 17391964 DOI: 10.1016/j.bmc.2007.03.013] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2007] [Revised: 03/01/2007] [Accepted: 03/08/2007] [Indexed: 11/19/2022]
Abstract
A series of phenyl acetic acid based quinolines was prepared as LXR modulators. An SAR study in which the C-3 and C-8 positions of the quinoline core were varied led to the identification of two potent LXR agonists 23 and 27. Both compounds displayed good binding affinity for LXRbeta and LXRalpha, and increased expression of ABCA1 in THP-1 cells. These two compounds also had desirable pharmacokinetic profiles in mice and displayed in vivo efficacy in a 12-week Apo E knockout mouse lesion model.
Collapse
Affiliation(s)
- Baihua Hu
- Chemical and Screening Sciences, Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, PA 19426, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Kaila N, Janz K, Huang A, Moretto A, DeBernardo S, Bedard PW, Tam S, Clerin V, Keith JC, Tsao DHH, Sushkova N, Shaw GD, Camphausen RT, Schaub RG, Wang Q. 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic Acid (PSI-697): Identification of a Clinical Candidate from the Quinoline Salicylic Acid Series of P-Selectin Antagonists. J Med Chem 2006; 50:40-64. [PMID: 17201409 DOI: 10.1021/jm060631p] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
P-selectin-PSGL-1 interaction causes rolling of leukocytes on the endothelial cell surface, which subsequently leads to firm adherence and leukocyte transmigration through the vessel wall into the surrounding tissues. P-selectin is upregulated on the surface of both platelets and endothelium in a variety of atherosclerosis-associated conditions. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of atherosclerosis. High-throughput screening and subsequent analoging had led to the identification of compound 1 as the lead candidate. Herein, we report the continuation of this work and the discovery of a second-generation series, the tetrahydrobenzoquinoline salicylic acids. These compounds have improved pharmacokinetic properties, and a number of them have shown oral efficacy in mouse and rat models of atherogenesis and vascular injury. The lead 31 (PSI-697), is currently in clinical development for the treatment of atherothrombotic vascular events.
Collapse
Affiliation(s)
- Neelu Kaila
- Chemical and Screening Sciences, Cardiovascular and Metabolic Disease, Drug Safety and Metabolism, Wyeth Research, Cambridge, Massachusetts 02140, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Hu B, Collini M, Unwalla R, Miller C, Singhaus R, Quinet E, Savio D, Halpern A, Basso M, Keith J, Clerin V, Chen L, Resmini C, Liu QY, Feingold I, Huselton C, Azam F, Farnegardh M, Enroth C, Bonn T, Goos-Nilsson A, Wilhelmsson A, Nambi P, Wrobel J. Discovery of Phenyl Acetic Acid Substituted Quinolines as Novel Liver X Receptor Agonists for the Treatment of Atherosclerosis. J Med Chem 2006; 49:6151-4. [PMID: 17034119 DOI: 10.1021/jm0609566] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A structure-based approach was used to optimize our new class of quinoline LXR modulators leading to phenyl acetic acid substituted quinolines 15 and 16. Both compounds displayed good binding affinity for LXRbeta and LXRalpha and were potent activators in LBD transactivation assays. The compounds also increased expression of ABCA1 and stimulated cholesterol efflux in THP-1 cells. Quinoline 16 showed good oral bioavailability and in vivo efficacy in a LDLr knockout mouse model for lesions.
Collapse
Affiliation(s)
- Baihua Hu
- Chemical and Screening Science, Cardiovascular and Metabolic Disease, and Bio Transformation and Disposition, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Clerin V, Nichol JW, Petko M, Myung RJ, Gaynor JW, Gooch KJ. Tissue engineering of arteries by directed remodeling of intact arterial segments. Tissue Eng 2003; 9:461-72. [PMID: 12857414 DOI: 10.1089/107632703322066642] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Traditional approaches to generating tissue-engineered arteries in vitro rely on expansion of cells in culture to seed appropriate scaffolds. In most envisioned applications, small autologous blood vessels would be harvested and used as a source for these cells. We propose that small autologous arteries, not the cells derived from them, may be an attractive starting point for engineered arteries. This approach capitalizes on the ability of intact arteries to grow and remodel in response to chronic changes in their mechanical environment. Carotid arteries from juvenile (approximately 30-kg) pigs were stretched longitudinally in an ex vivo perfusion system over 9 days. This resulted in a 40% increase in artery length at physiological longitudinal stress and a 20 +/- 3% increase when unstressed. Control arteries were perfused for 9 days ex vivo at their physiological loaded length. Control and elongated arteries displayed native appearance (macroscopic and histological), excellent viability (cellularity and mitochondrial activity), normal vasoactivity, and similar mechanical properties (ultimate stress and ultimate strain) as compared with freshly harvested arteries. Growth, as opposed to just redistribution of existing mass, contributed to elongation as evidenced by an increase in artery weight. Results on elongation of arteries from neonatal and adolescent pigs are also presented and discussed.
Collapse
|
15
|
Clerin V, Gusic RJ, O'Brien J, Kirshbom PM, Myung RJ, Gaynor JW, Gooch KJ. Mechanical environment, donor age, and presence of endothelium interact to modulate porcine artery viability ex vivo. Ann Biomed Eng 2003; 30:1117-27. [PMID: 12502223 DOI: 10.1114/1.1519262] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Though ex vivo culture of arteries is a widely used model of native arteries and is closely aligned with efforts to generate tissue-engineered arteries, the effects of culture conditions on artery viability are poorly characterized. To investigate factors regulating long-term viability of cultured arteries, carotid arteries from neonatal and adolescent pigs were perfused for up to 27 days with steady laminar flow ranging from approximately 2% to approximately 200% of physiological flow rates. Arteries from neonatal animals (2 weeks old, approximately 5 kg) were susceptible to spontaneous progressive endothelial denudation followed by deterioration of the vessel wall that spread from luminal to abluminal regions. Subphysiological levels of flow and pressure abrogated this deterioration. Arteries harvested from adolescent (6 months old, approximately 100 kg) animals maintained viability and retained structure for at least 9 days as assessed by normal histology, presence of intact endothelium, normal mitochondrial activity, and low levels of cell death and proliferation, unless the vessels were subjected to superphysiological levels of flow or the endothelium was intentionally denuded. Adolescent arteries perfused at subphysiological, but not physiological, flow rates maintained viability and normal structure for at least 27 days. These data indicate that under the appropriate conditions, arteries may be cultured long term but careful attention to the viability is merited.
Collapse
Affiliation(s)
- V Clerin
- Department of Bioengineering and Institute of Medicine and Engineering, University of Pennsylvania, PA, USA
| | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
BACKGROUND Explant analysis of left ventricular assist systems (LVAS) should permit a better evaluation of long-term evolution of materials and tissue healing in patients supported by mechanical devices and a precise understanding of embolic phenomena, observed clinically. METHODS Five Novacor LVAS and their conduits have been explanted after 156 days (range 61-226 days) of mechanical support. The pseudo-intima (PI) developed in the inflow and outflow conduits was characterized microscopically, using monoclonal antibodies. RESULTS The morphological aspects of PI were quite different in the inflow and outflow conduits. Blood coagulation between the basal surface of the PI and the Dacron tube, irregular collagen type I matrix with plasma infiltration, macrophages, and neutrophil granulocyte elastase characterized the nonadherent, loose, and potentially thrombogenic PI growth in the inflow conduit. The PI from collagen types I and IV with circumferentially oriented alpha-smooth muscle cell actin-positive cells was anchored to the outflow conduits. CONCLUSIONS The observations, which have to be confirmed by a more extensive study on a larger number of specimens, suggest the role of the biomaterial itself, as well as the configuration, physical characteristics, and rheology in the conduit. They also suggest that thromboembolic complications of LVAS may eventually be related to this host tissue response.
Collapse
Affiliation(s)
- R Houel
- Department of Cardiothoracic and Cardiovascular Surgery, Hôpital Henri Mondor, Créteil, France
| | | | | | | |
Collapse
|